Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: Claseprubart in Multifocal Motor Neuropathy
NCT06537999Phase 2Active, not recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of claseprubart in multifocal motor neuropathy (MMN) (3 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events. Started Sep 2024; status: active, not recruiting.
02
Drugs
claseprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT06537999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537999.